Skip to content
Companies

Entact Bio

Oral drugs that enhance proteins instead of blocking them

Raised to date

$10M

of $10M offered across 1 Form D filing

Investors
7
Last filed
Jun 3, 2026

About

Entact Bio is a preclinical-stage biotechnology company in Watertown, Massachusetts developing small-molecule medicines that enhance the function of beneficial proteins rather than inhibiting or degrading them. Its Encompass platform designs ENTACs (Enhancement-Targeting Chimeras), orally available bifunctional molecules that act as molecular matchmakers between a target protein and a deubiquitylase (DUB), harnessing the DUB's natural activity to extend a protein's lifespan, relocate it to the correct cellular compartment, or modify its activity. The company was founded in 2021 by a team rooted in DUB biochemistry and chemical biology and launched publicly in 2023 with an $81 million Series A co-led by Qiming Venture Partners USA and venBio Partners. It is led by CEO Victoria Richon, previously President and CEO of Ribon Therapeutics and global head of oncology research at Sanofi.

Most induced-proximity drug discovery removes proteins; Entact runs the mechanism in reverse, recruiting deubiquitylases to rescue and boost proteins that disease has lost, mislocated, or silenced - reaching targets that inhibitors and degraders structurally cannot address.

Funding

  • EquityFiled Jun 3, 2026Form D
    $10M/ $10M

Product

Encompass platform

Drug discovery platform

A discovery and optimization platform for ENTAC medicines - bifunctional small molecules that bring a target protein together with a deubiquitylase so the DUB's natural activity enhances that protein's function. The platform systematically tests DUB-substrate combinations to inform rational ENTAC design.

  • Enhancement-Targeting Chimera (ENTAC) molecular design
  • Deubiquitylase (DUB) recruitment for targeted protein rescue
  • Orally available bifunctional small molecules

Built for

Patients with genetic disorders and complex diseases driven by insufficient, mislocalized or destabilized proteins, reached through biopharmaceutical development and partnerships

People on file